Latest News: Proscia Receives FDA 510(k) Clearance For Concentriq AP-DxREAD THE PRESS RELEASE

Proscia Receives FDA 510(k) Clearance For Concentriq AP-Dx

Proscia
By Author Proscia | February 12, 2024

In support of its 510(k) clearance, Proscia conducted a multi-site clinical study at PathGroup, South Bend Medical Foundation, and Spectrum Healthcare Partners. The study demonstrated that diagnoses made on Concentriq AP-Dx are non-inferior to traditional glass slide reads.

Our website uses cookies. By using this site, you agree to its use of cookies.